Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration has approved the Nuvaxovid™ 2025-2026 Formula for the prevention of COVID-19 in adults 65 years and older or individuals 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

The FDA has approved an updated COVID-19 booster while limiting access to high-risk individuals, amid ongoing debates on vaccine safety and efficacy.

CVS and Walgreens are reportedly scaling back access to updated COVID-19 vaccines in several states following new federal guidelines that limit eligibility to only seniors and high-risk groups.  Based on the "current regulatory environment,

A once-straightforward COVID-19 vaccine process has become muddled this year because of new federal guidance on who the shots are approved for.

Parents will still be able to seek out shots from rival drugmaker Moderna, the other maker of mRNA vaccines, which has full FDA approval for children as young as 6 months. But the company’s Spikevax vaccine is only approved for children with at least one serious health problem.

The FDA approved updated COVID-19 vaccines for people 65 and older and younger adults and children with underlying medical conditions.

COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating